3B Future Health Fund, previously known as Helsinn Investment Fund S.A., SICAR has announced this week that it has invested in iOnctura SA, a clinical stage biopharmaceutical company developing a pipeline of next generation molecules targeting cancer and fibrosis.
3B Future Health Fund is focused on investments in areas of high unmet patient need. Backed by the Helsinn Group, and guided by Helsinn’s core values of quality, integrity and respect, 3B Future Health Fund aims to help companies with innovative technologies to transform new ideas into commercial solutions with the potential to impact health-related quality of life of patients.
Drawing on Helsinn’s over 40 years of investment into research and development and commercial expertise, the investment fund selects companies with technologies in a range of areas including cancer therapeutics and diagnostics, cancer supportive care, metabolic disorders, and dermatology conditions.
“We look to invest in early-stage companies which are developing novel treatments in areas of high unmet patient need. We have been very impressed with the world class team at iOnctura and the potential of its next generation molecules targeting cancer and fibrosis.”Riccardo Braglia, 3B Future Health Fund Chairman and Helsinn Group Vice Chairman and Chief Executive Officer
iOnctura SA was founded in June 2017 as a spin out from Merck and seed funded by M Ventures, the strategic corporate venture capital arm of Merck. It has raised an additional EUR 5.1 million bringing iOnctura’s total Series A financing to EUR 20.1 million. 3B Future Health Fund joins the existing blue-chip investor syndicate of M Ventures,INKEF Capital, VI Partners, and Schroder Adveq, which all participated in the extension.
The funding will enable iOnctura to accelerate development of its next generation dual immune and tumour targeting therapies.